Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer

Locally advanced breast cancer (LABC) cases have a varying five-year survival rate, mainly influenced by the tumor response to chemotherapy. Paclitaxel activity (response rate) varies across populations from 21.5% to 84%. There are some reports on genetic traits and paclitaxel; however, there is sti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Perez-Ortiz, Andric C., Ramírez, Israel, Cruz-López, Juan C., Villarreal-Garza, Cynthia, Luna-Angulo, Alexandra, Lira-Romero, Esmeralda, Jiménez-Chaidez, Salvador, Díaz-Chávez, José, Matus-Santos, Juan A., Sánchez-Chapul, Laura, Mendoza-Lorenzo, Patricia, Estrada-Mena, Francisco J.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739747/
https://ncbi.nlm.nih.gov/pubmed/29290962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22461
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados